Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-02-10FDA Approved: OLANZAPINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for olanzapine from Dr. Reddy's Laboratories Limited (ANDA 076534), authorizing a generic olanzapine…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia [Phase 3]
A Phase 3 clinical trial evaluating the efficacy and safety of lurasidone HCl in acutely psychotic patients with schizophrenia has completed…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules [Phase 2]
A Phase 2 multiple-dose study evaluated safety, tolerability, and pharmacokinetics of risperidone extended-release capsules in schizophrenia…
-
CLINICAL_TRIALS trial_result · 2023-02-06Clinical Trial Update: Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors [NA]
Clinical trial update related to acetylcholine, tobacco smoking, genes, and nicotinic receptors; completed with results posted.
-
FDA approval · 2023-02-03FDA Approved: BREXPIPRAZOLE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s original application for brexpiprazole (brexpiprazole), authorizing a generic version of the antipsych…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-01-31FDA Approved: ARIPIPRAZOLE — Supplemental Application (VistaPharm, LLC)
FDA approved a supplemental application for aripiprazole filed by VistaPharm, LLC, marking approval of a supplemental submission for this ge…
-
CLINICAL_TRIALS trial_result · 2023-01-31Clinical Trial Update: Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN) [NA]
Clinical trial update on biomarker and safety study of clozapine in patients with benign ethnic neutropenia (BEN) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-01-26Clinical Trial Update: A Study of Cognitive Adaptation Training in Inpatient Forensic Environments
A completed clinical trial evaluating Cognitive Adaptation Training in inpatient forensic settings for schizophrenia.
-
CLINICAL_TRIALS trial_result · 2023-01-19Clinical Trial Update: Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder [Phase 3]
A Phase 3 trial evaluating ALKS 3831 for body weight effects in young adults recently diagnosed with schizophrenia, schizophreniform disorde…
-
CLINICAL_TRIALS trial_result · 2023-01-18Clinical Trial Update: Circuitry-Guided Smoking Cessation in Schizophrenia [NA]
A completed clinical trial investigating circuitry-guided smoking cessation in individuals with schizophrenia; results posted in 2023.
-
FDA approval · 2023-01-13FDA Approved: RYKINDO EXTENDED-RELEASE MICROSPHERES — Original Application (Shandong Luye Pharmaceutical Co., Ltd.)
FDA approved RYKINDO EXTENDED-RELEASE MICROSPHERES, an oral extended-release formulation of risperidone from Shandong Luye Pharmaceutical, u…
-
FDA approval · 2023-01-05FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s original application for fluphenazine hydrochloride, a generic antipsychotic. The approval confirms th…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study [NA]
A completed clinical trial evaluating transcranial magnetic stimulation targeting the cerebellum for schizophrenia-related psychosis with re…
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Restoration of Cognitive Function With TDCS and Training in Serious Mental Illness [NA]
Completed clinical trial investigating transcranial direct current stimulation (TDCS) plus training to restore cognitive function in serious…
-
CLINICAL_TRIALS trial_result · 2022-12-21Clinical Trial Update: Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia [Phase 4]
Phase 4 trial update on memantine's effects for sensorimotor gating and neurocognition in schizophrenia.
-
EMA approval · 2022-12-20EMA Authorised: Olanzapine Glenmark Europe (olanzapine) — Glenmark Arzneimittel GmbH
Authorised olanzapine product (Glenmark Europe) for schizophrenia and bipolar disorder.
-
EMA approval · 2022-12-20EMA Authorised: Olanzapine Glenmark (olanzapine) — Glenmark Arzneimittel GmbH
Glenmark's olanzapine product has been authorised for schizophrenia and bipolar disorder in the EU.
-
FDA approval · 2022-12-19FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for Clozaril (clozapine) filed by HLS Therapeutics (USA), Inc.
-
FDA approval · 2022-12-15FDA Approved: PERSERIS — Supplemental Application (Indivior Inc.)
FDA approved a supplemental application for Perseris (risperidone) from Indivior Inc.
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Treatment of Negative Symptoms and Schizophrenia [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial investigating treatment for negative symptoms in schizophrenia conducted by University Hospital, Montpe…
-
FDA approval · 2022-12-13FDA Approved: LURASIDONE HYDROCHLORIDE — Original Application (Ascend Laboratories, LLC)
FDA approved lurasidone hydrochloride tablets as a generic Original Application for the treatment of schizophrenia and depressive episodes a…
-
CLINICAL_TRIALS trial_result · 2022-12-12Clinical Trial Update: A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia [Phase 4]
A Phase 4 study evaluating agomelatine in combination with antipsychotics for negative symptoms in schizophrenia; current status is unknown.
-
FDA label_change · 2022-12-02FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved Janssen's supplemental application for Risperdal M-TAB (risperidone), updating labeling and introducing the M-TAB dosage form.
-
CLINICAL_TRIALS trial_result · 2022-11-22Clinical Trial Update: Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients [Phase 4]
A Phase 4 trial evaluating a fixed-dose intervention to enhance survival in patients with serious mental illness, including schizophrenia an…
-
CLINICAL_TRIALS trial_result · 2022-11-21Clinical Trial Update: Levetiracetam in Early Psychosis [Phase 2]
Phase 2 trial update evaluating levetiracetam in early psychosis has been completed with results posted in 2022.